Contract research organization Inotiv announced a partnership with Lithuanian multi‑omics analytics firm Vugene to integrate AI‑driven bioinformatics into early‑stage discovery workflows. The agreement will combine Inotiv’s preclinical services with Vugene’s platform that interprets genomics, proteomics, metabolomics and other omics layers to improve predictions of drug efficacy and safety. Inotiv cited the move as a capability enhancement to accelerate go/no‑go decisions for clients. Financial terms were not disclosed; the collaboration targets tighter translational links between complex datasets and candidate selection.